Current Trials
All study-related visits, tests, and drugs will be provided at no cost. In addition, reimbursement for time and travel may be provided. You do not need to be a current patient of Atlanta Allergy & Asthma to participate in a research study.
Participants Needed for Peanut Allergy Study: Epicutaneous Peanut Immunotherapy
Qualifications to be considered for this study:
- Children ages 4 to 11
- Physician -diagnosed peanut allergy or children with a well-documented medical history of Ige-mediated reaction(s) after ingestion with peanut. (Children with a history of anaphylaxis, including severe anaphylaxis to peanut will be eligible)
- Peanut-specific positive peanut skin prick test and peanut blood test Not currently on immunotherapy for any allergen (including environmental & insect allergy)
- No monoclonal antibody therapy within 6 months of screening
- No uncontrolled persistent asthma
To learn more, please contact Martha Coggins at our Stockbridge Research facility.
Phone: 770.996.5354
Email: [email protected]
Participants Needed for Chronic Spontaneous Urticaria (CSU) Study:
Qualifications to be considered for this study:
- Ages 18 and up
- CSU duration greater than 6 months
- CSU inadequately controlled by H1-antihistamines
- Documentation of hives within 3 months before screening
- Willing to complete a urticaria patient daily diary for the duration of the study
- Participants cannot have monoclonal antibody treatment within 4 months of screening
To learn more, please contact Martha Coggins at our Stockbridge Research facility.
Phone: 770.996.5354
Email: [email protected]
Participants Needed for Peanut Allergy Study:
Qualifications to be considered for this study:
- Ages 6 to 55
- Documented medical history of allergy to peanuts or peanut containing foods
- Participants must be able to receive injections (study treatment)
- No uncontrolled asthma
- No monoclonal antibody treatment within 6 months of screening
To learn more, please contact Janet Plumley at our Kennestone Research facility.
Phone: 770.592.4210
Email: [email protected]